Marinus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Marinus Pharmaceuticals

08/05/2024 14:53

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of 68 cents​​ per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -67 cents.  The mean expectation of
eleven analysts for the quarter was for a loss of 66 cents per
share. Wall Street expected results to range from -79 cents
to -61 cents per share.
    * Revenue fell 26.2% to $7.66 million from a year ago;
analysts
expected $9.13 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 68 cents​.
    * The company reported a quarterly loss of $38.67 million.
    * Marinus Pharmaceuticals Inc shares had fallen by 82.6%
this
quarter and lost 85.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 13.2%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $7.50 

This summary was machine generated from LSEG data May 8 at 01:53
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.66          -0.68          Missed
 Dec. 31 2023      -0.62          -0.74          Missed
 Sep. 30 2023      -0.66          -0.61          Beat
 Jun. 30 2023      -0.72          -0.61          Beat